BioSpace News Archive

Akero Therapeutics, Inc. (Nasdaq: AKRO) will hold an investor conference on Tuesday, October 10 at 8:00 a.m. ET to share topline week 36 results from its SYMMETRY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH).

Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), announced it has received Investigational Device Exemption (IDE) approval from the FDA for a subsequent multicenter study, PROACTIVE-HF 2, which will evaluate the company’s Cordella Sensor for pulmonary artery (PA) pressure-guided therapy.

Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the complete results from the open-label EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis.

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced completion of enrollment in a randomized, double-blind, placebo-controlled phase 2 study of LD IL-2 in patients with mild-to-moderate AD.

Harmonic Bionics announced today that Barrow Neurological Institute (part of Dignity Health) in Phoenix, AZ has purchased two Harmony SHR™ exoskeletons to be used in the hospital’s inpatient and outpatient programs.

SenesTech, Inc. (NASDAQ: SNES) today announced that Joel Fruendt, Chief Executive Officer, and Tom Chesterman, Chief Financial Officer, will present and host one-on-one meetings with investors at the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023.

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2023 financial results before the market opens on Wednesday, November 1, 2023.

Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 18,000 shares of its common stock with an exercise price of $1.15 per share, which is equal to the closing price of Kezar’s common stock on October 2, 2023, the grant date of the award.

Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) announced today that Quang Pham, CEO, will be participating in a Company Webcast and Panel Presentation at the Lytham Partners Fall 2023 Investor Conference on Tuesday, October 17, 2023.

Poseida Therapeutics, Inc. announced the appointment of Mark Gergen as Executive Chairman and the transition of Kristin Yarema, Ph.D., currently President, Cell Therapy, to the role of President and Chief Executive Officer, each expected to be effective January 1, 2024.